Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Insys Therapeutics Inc    INSY

INSYS THERAPEUTICS INC

(INSY)
My previous session
Most popular
  Report  
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsOfficial PublicationsSector newsAnalyst Recommendations

Insys Therapeutics' : auditor raises going concern doubts, shares drop

share with twitter share with LinkedIn share with facebook
share via e-mail
0
03/13/2019 | 11:35am EDT
Pharmaceutical tablets and capsules are arranged on a table in this picture illustration taken in Ljubljana

(Reuters) - Insys Therapeutics Inc said on Wednesday its auditor raised doubts on the drugmaker's ability to continue as a going concern, sending its shares down 13 percent.

The Arizona-based company said the auditor's opinion on the audited financial statements for the year ended Dec. 31, 2018 flags uncertainty in its ability to generate enough cash to meet its legal obligations and sustain operations.

Insys said that while it is looking for ways to raise capital, it can provide "no assurances" on the success of its efforts or that it would resolve its liquidity issues and wipe out operating losses.

"If we are unable to obtain sufficient funding, we would need to significantly reduce our operating plans and curtail some or all of our product development, commercialization and strategic plans," the company said in a regulatory filing.

Last week, Insys said it had hired Lazard to advise on its plans to explore strategic options and is in talks to divest its fentanyl sublingual spray Subsys.

The company had come under fire for its marketing practices related to Subsys, an opioid that is 100 times stronger than morphine.

Insys' former Chief Executive Officer Michael Babich in January pleaded guilty to participating in a nationwide scheme to bribe doctors to prescribe the addictive opioid medication.

Shares of the company fell 13 percent to $4.94 in morning trading.

(Reporting by Saumya Sibi Joseph in Bengaluru; Editing by James Emmanuel)

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on INSYS THERAPEUTICS INC
03/13MARKET SNAPSHOT: S&P 500 Ends At 4-month High As Stocks Rise After Strong Eco..
DJ
03/13INSYS THERAPEUTICS' : auditor raises going concern doubts, shares drop
RE
03/13INSYS THERAPEUTICS : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION..
AQ
03/07INSYS THERAPEUTICS, INC. : Results of Operations and Financial Condition, Financ..
AQ
03/07INSYS Therapeutics Reports Fourth Quarter and Full Year 2018 Results
GL
03/07INSYS THERAPEUTICS : Summary Toggle, INSYS Therapeutics to Report Fourth Quarter..
AQ
03/06INSYS THERAPEUTICS : to Report Fourth Quarter and Full Year 2018 Results on Marc..
AQ
03/04EXCLUSIVE : OxyContin maker Purdue Pharma exploring bankruptcy - sources
RE
02/26INSYS THERAPEUTICS : Presented Poster of Initial Pharmacokinetic Study of Epinep..
AQ
02/25INSYS THERAPEUTICS : Presented Poster of Initial Pharmacokinetic Study of Epinep..
AQ
More news
Financials ($)
Sales 2019 60,3 M
EBIT 2019 -61,7 M
Net income 2019 -98,0 M
Debt 2019 -
Yield 2019 -
P/E ratio 2019 -
P/E ratio 2020
Capi. / Sales 2019 5,44x
Capi. / Sales 2020 4,15x
Capitalization 328 M
Chart INSYS THERAPEUTICS INC
Duration : Period :
Insys Therapeutics Inc Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends INSYS THERAPEUTICS INC
Short TermMid-TermLong Term
TrendsBearishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 6
Average target price 7,83 $
Spread / Average Target 78%
EPS Revisions
Managers
NameTitle
Saeed Motahari President, Chief Executive Officer & Director
Steven J. Meyer Chairman
Andrew G. Long CFO & Principal Accounting Officer
Venkat Reddy Goskonda Vice President-Research & Development
Ahmed Elkashef Vice President-Clinical Development
Sector and Competitors
1st jan.Capitalization (M$)
INSYS THERAPEUTICS INC26.00%328
GILEAD SCIENCES1.95%81 339
VERTEX PHARMACEUTICALS10.17%46 409
REGENERON PHARMACEUTICALS4.90%42 066
GENMAB8.01%10 747
SAREPTA THERAPEUTICS INC12.03%9 008